Evaluation of the Efficacy of Nasal Sedation Midazolam Compared with Dexmedetomidine in the Management of Uncooperative Children with Down Syndrome during Dental Treatment

Table 6

Results of vital sign analyzes.

	Stages	Sedation methods	Mean	SD	t-value	value
SBP	Before treatment	Dexmedetomidine	102.50	3.25	−1.672	0.31
		Midazolam	102.83	2.92
	During treatment	Dexmedetomidine	100.36	3.91	3.272	0.015
		Midazolam	95.55	3.18
	After treatment	Dexmedetomidine	101.95	2.87	−2.021	0.23
		Midazolam	103.21	2.66
DBP	Before treatment	Dexmedetomidine	68.97	2.96	−2.034	0.83
		Midazolam	69.42	3.22
	During treatment	Dexmedetomidine	67.12	3.72	1.462	0.17
		Midazolam	65.89	4.05
	After treatment	Dexmedetomidine	69.28	3.53	0.945	0.42
		Midazolam	68.45	3.55
PR	Before treatment	Dexmedetomidine	106.5	9.7	2.580	0.266
		Midazolam	105.8	8.9
	During treatment	Dexmedetomidine	99.7	6.5	−1.044	0.011
		Midazolam	106.4	8.2
	After treatment	Dexmedetomidine	105.5	7.3	−1.053	0.122
		Midazolam	106.2	8.3
SpO2	Before treatment	Dexmedetomidine	98.22	2.32	0.985	0.263
		Midazolam	97.73	3.86
	During treatment	Dexmedetomidine	97.96	1.97	1.032	0.722
		Midazolam	95.32	3.89
	After treatment	Dexmedetomidine	99.11	2.90	1.572	0.484
		Midazolam	96.75	4.21